Vetter Wins Frost & Sullivan Award
News Jul 15, 2011
Leading contract development and manufacturing organization (CDMO) Vetter has received the Frost & Sullivan 2011 European Prefilled Injection Systems Customer Service Leadership Award.
The international consulting company recognized Vetter for best practices in its collaboration with global customers, in particular, the added value due to the outstanding quality of service the company creates for its partners.
Vetter plays a significant role in the success of its clients by providing crucial support from early development of drugs through regulatory approval and market supply worldwide. The award ceremony is to be held on September 29 in London ( Great Britain).
Prior to granting the award, Frost & Sullivan examined service providers from the global pharmaceutical and biotech industries focusing on four criteria: quality, timeliness, customer benefits and cost of services. These criteria were analyzed both qualitatively and quantitatively, taking into account the current situation and trends in the market.
Following this extensive analysis, Vetter was selected as the 2011 European Prefilled Injection Systems Customer Service Leadership Award recipient.
In explaining its decision, Frost & Sullivan’s Program Manager, Ranjith Gopinathan said, “Vetter is renowned for its quality, innovation and loyalty as a strategic partner for pharmaceutical and biotech clients. As a leading CDMO, Vetter offers its customers “service throughout all stages of a drug’s development and through all the lifecycles, providing the necessary support at all times.”
Vetter is specialized in working with complex substances and has extensive experience with a broad array of compounds, including monoclonal antibodies, peptides, interferons and vaccines.
He further explained, “this will provide the pharmaceutical company with valuable time and resources to concentrate on core activities, namely research and development into other drugs and marketing.”
Vetter managing director Peter Soelkner was thrilled with the news. “This recognition by Frost & Sullivan, one of the most prestigious international consulting firms is an impressive achievement,” he said.
Soelkner continued, “However, we do not view the award as an end in itself. Rather, it is a justification of our business model of resolute customer orientation and a challenge to exceed even our high business standards. We will continue to make every effort to provide our customers with the best possible support available, helping them to secure their success in the global marketplace.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE